NovaBay® Pharmaceuticals, Inc. (NYSE-AMEX:NBY) announces that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will be presenting at the 7th Annual Spring Growth Stock Conference hosted by Security Research Associates, Inc. The conference will be held on Tuesday, May 24 at the Omni Hotel in San Francisco. Dr. Najafi’s presentation is scheduled for 12:00 p.m. to 12:30 p.m. Pacific Daylight Time in the Nob Hill Presentation Room.
Conference attendees will include a select group of institutional portfolio managers and analysts, and will feature CEOs and CFOs from approximately three dozen of the fastest-growing companies in the technology and life sciences sectors.
To access a webcast of Dr. Najafi’s presentation, please access the following link:http://www.wsw.com/webcast/sra12/nby/
About Security Research Associates, Inc.
Security Research Associates, Inc. (SRA) was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services. A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas. For more information about SRA see our web site at www.sracap.com or call us at 415-925-0346.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 gel for impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for conjunctivitis. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the potential for urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase®, which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit www.novabaypharma.com
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
Investors and Media:
The Investor Relations Group